Volume : 13, Issue : 08, August – 2026

Title:

DEVELOPMENT AND VALIDATION OF NEW ANALYTICAL METHOD FOR THE DETERMINATION OF IBRUTINIB IN BULK AND TABLET DOSAGE FORM

Authors :

Sneha N U*, Suresha D N, Naveen Kumar G S

Abstract :

Simple, precise and accurate area under curve spectroscopic method has been developed and validated for the determination of Ibrutinib in bulk and tablet dosage form. The drug shows maximum absorption (λ max) at 258nm in Acetonitrile solution and Area under Curve [AUC] in absorption spectra were measured between the wavelength range 253 to 263nm which obeys Beer’s law in the concentration range of 2-12 µg/ml. The linearity study was carried out and regression coefficient was found to be 0.9999 and it has showed good linearity, precision during this concentration range. The % recovery was found to be 99.61- 99.99. The LOD and LOQ were found to be 0.0396 and 0.12µg/ml. The % relative standard deviation was found to be less than 2. According to ICH guidelines the method has been validated for linearity, precision, accuracy, robustness, ruggedness, LOD and LOQ. The developed and validated method can be successfully applied for routine quantitation of Ibrutinib in bulk and tablet dosage form.
Keywords: Ibrutinib, Area under curve spectroscopy, validation, pharmaceutical formulations.

Cite This Article:

Please cite this article in press Sneha N U et al., Development And Validation Of New Analytical Method For The Determination Of Ibrutinib In Bulk And Tablet Dosage Form. Indo Am. J. P. Sci, 2026; 13(08).

REFERENCES:

1. Akbel E, Güngör S, Bulduk İ. Alternative analytical methods for ibrutinib quantification in pharmaceutical formulation: A statistical comparison. Reviews in Analytical Chemistry. 2022 Jul 20;41(1):146-57.
2. Mehta L, Naved T, Grover P, Bhardwaj M, Mukherjee D. Development and validation of novel and highly sensitive stability-indicating reverse phase ultra performance liquid chromatography method for quantification of Ibrutinib and its ten degradation products. Indian Journal of Pharmaceutical Sciences. 2020 Dec 1;82(6):958-66.
3. Hepsebah NJ, Kumar AA. Bioanalytical method development and validation of ibrutinib in biological matrices by LC-MS/MS. Int J Pharm Pharm Sci. 2019;11:22-6.
4. Sultana S, Havannavar NT, Fathima H. Determination of ibrutinib in dosage form and in bulk drug by UV spectrophotometric and colorimetry methods.
5. Konduru N, Gundla R, Katari NK, Paidikondala K, Reddy AS, Jagadabi V. Development and validation of a stability-indicating method for ibrutinib: Identification and separation of degradation products, known and genotoxic impurities using RP-HPLC/PDA and QDa mass detectors. Analytical Chemistry Letters. 2020 Jan 2;10(1):113-36.
6. Bindu GH, Annapurna MM. A sensitive stability indicating RP-HPLC method for the determination of Ibrutinib-An anti-cancer drug. Research Journal of Pharmacy and Technology. 2018;11(10):4587-91.
7. Prasad SS, Mohan GK, Babu AN. A quality by design approach for development of simple and robust reversed phase stability indicating HPLC method for determination of ibrutinib and its impurities. analytical methods. 2019 Jul;12(3):1434-45.
8. Uppala V, Divya N, Charishma E, Harshavardan K. PHARMACEUTICAL SCIENCES.
9. Validation of stability indicating RP-HPLC method for the assay of ibrutinib in pharmaceutical dosage form.
10. Gopireddy RR, Maruthapillai A, Mahapatra S. A stability indicating method development and validation for separation of process related impurities and characterization of unknown impurities of tyrosine kinase inhibitor ibrutinib using QbD approach by RP-HPLC, NMR spectroscopy and ESI-MS. Journal of chromatographic science. 2021 Oct;59(9):830-46.
11. Illendula S, Sharma S. UPLC method development and validation of acalabrutinib in bulk and pharmaceutical dosage form. Internatiolnal jouirnal of chemical and biochemical Sciences (IJCBS). 2024;25(14):397-411.
12. Mehta L, Naved T, Grover P, Bhardwaj M, Mukherjee D. Development and validation of novel and highly sensitive stability-indicating reverse phase ultra performance liquid chromatography method for quantification of Ibrutinib and its ten degradation products. Indian Journal of Pharmaceutical Sciences. 2020 Dec 1;82(6):958-66.
13. Sun S, Cheng D, Kong S, Li X, Li T, Yu Q, Wang L. A rapid and sensitive method for quantification of ibrutinib in rat plasma by UPLC–ESI–MS/MS: validation and application to pharmacokinetic studies of a novel ibrutinib nanocrystalline. Biomedical Chromatography. 2020 Jan;34(1):e4703.
14. Hepsebah NJ, Kumar AA. Bioanalytical method development and validation of ibrutinib in biological matrices by LC-MS/MS. Int J Pharm Pharm Sci. 2019;11:22-6.
15. ICH, Q2A Text on Validation of Analytical Procedures; 1994.
16. ICH, Q2B Validation of Analytical Methodology; 1996.
17. ICH, Q2 (R1) Validation of Analytical Procedures: text and methodology; 2005.

Volume : 13, Issue : 08, August – 2026

Title:

EVALUATION OF ANTIHYPERLIPIDEMIC ACTIVITY OF SAPINDUS EMARGINATUS IN RATS

Authors :

Chinthala Jamima*, Dr.R.narasimha Rao, Dr.N. Raghunandhan

Abstract :

Obesity and hyperlipidemia have become major disorders predominantly causing prevailing cardiovascular diseases and ultimately death. The prolonged use of anti-obesity drugs and statins for reducing obesity and blood lipid levels is leading toward adverse effects of kidneys and muscles, specifically rhabdomyolysis. The objective of this study is to evaluate potential of seeds of Sapindus emarginatus against hyperlipidemia. In this model of Hyperlipidemia, 30 adult male wistar rats (200-250gms) were evenly divided into 5 groups in both groups. Group-1 and Group-2 served as untreated and model controls respectively, while Group-3, 4 and 5 were the treatments groups which were simultaneously treated with standard, 100 and 200 mg/kg extract respectively along with High Fat Diet. On last day, blood samples for biochemical parameters, were obtained under inhaled diether anaesthesia. The outcomes of this study were expressed as mean standard error and data were evaluated by using analysis of variance followed by multiple comparisons. Oral administration of 100 mg/ kg and 200mg/kg body weight of Methanolic extract residual fraction of Moringa oleifera. Leaves exhibited a significant reduction (P < 0.01) in serum lipid parameters such as triglycerides, total cholesterol, low density lipoprotein (LDL), very LDL and increase in high density lipoprotein in hyperlipidemic rats when compared with hyperlipidemic control in both models. Our results demonstrated that Methanolic extract fraction of Sesbania grandiflora. Possessed significant antihyperlipidemic activity.
Keywords: Sesbania grandiflora, Cholesterol, LDL, triglycerides and antihyperlipidemic activity.

Cite This Article:

Please cite this article in press Chinthala Jamimaet al., Evaluation of Antihyperlipidemic activity of Sapindus Emarginatus in rats,, Indo Am. J. P. Sci, 2026; 13(08).

REFERENCES:

1. Amit G, Vandana S, Sidharth M. HYPERLIPIDEMIA: An Updated Review. Inter J of Biopharma & Toxicol Res 2011;1:81-89.
2. Virchow RP, Thrombose IG. In Gesammelte Abhandlungen zur Wissenschaftlichen Medicin. Frankfurt-am-Main, Meidinger Sohn & Company 1856, S 458-564.
3. Ankur rohilla, Nidhi Dagar, Seema Rohilla, Amarjeet Dahiya, Ashok Kushnoor. HYPERLIPIDEMIA- a deadly pathological condition. Inter J Curr Pharma Res 2012;4:15-18
4. Ross R, Glomset JA. The pathogenesis of atherosclerosis. N Engl J Med 1976;295:369-77.
5. Grundy SM, Vega GL. Hypertriglyceridemia: causes and relation to coronary heart disease – Semin. Thromb. Hemost 1988;14:249-64.
6. Dargel R. Lipoproteins and the etiopathogenesis of atherosclerosis. Zentralbl Allg Pathol 1989; 135: 501-504.